1131P Overall survival after treatment with first-line crizotinib or alectinib in patients with stage IV NSCLC and ALK rearrangement: A real-world nationwide cohort study from the Netherlands
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2022 |
| Reihe/Periodikum: | Annals of Oncology ; volume 33, page S1068 ; ISSN 0923-7534 |
| Verlag/Hrsg.: |
Elsevier BV
|
| Schlagwörter: | Oncology / Hematology |
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-26791398 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | http://dx.doi.org/10.1016/j.annonc.2022.07.1255 |
